Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010177 | 1.00 | ALDH1A1 (0.77) | ALDH1A1PKMPOLBKMT2ACYP2D6 | |
| SCHEMBL592660 | 0.90 | POLB (0.64) | ALDH1A1PKMPOLBKMT2ACYP2D6 | |
| SCHEMBL2304471 | 0.87 | ALDH1A1 (1.00) | ALDH1A1PKMPOLBKMT2AMEN1 | |
| SCHEMBL1563867 | 0.87 | ALDH1A1 (1.00) | ALDH1A1PKMPOLBKMT2AMEN1 | |
| SCHEMBL2307309 | 0.86 | ALDH1A1 (0.74) | ALDH1A1PKMPOLBKMT2ACYP2D6 | |
| SCHEMBL7033312 | 0.83 | ALDH1A1 (0.74) | ALDH1A1PKMPOLBKMT2ACYP2D6 | |
| SCHEMBL6386661 | 0.82 | ALDH1A1 (0.90) | ALDH1A1PKMPOLBKMT2AMEN1 | |
| SCHEMBL11688646 | 0.82 | ALDH1A1 (0.52) | ALDH1A1PKMPOLBKMT2ACYP2D6 | |
| SCHEMBL3073609 | 0.81 | ALDH1A1 (0.51) | ALDH1A1PKMPOLBKMT2ACYP2D6 | |
| SCHEMBL11257389 | 0.81 | ALDH1A1 (0.62) | ALDH1A1PKMPOLBKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046227-A1 | X-RAY VISIBLE IMPLANTABLE SCAFFOLDS | UCL BUSINESS LTD (GB) | 2025-03-06 | — | — | WO | claimed |
| WO-2021153823-A1 | METHOD FOR PREPARING CHITOSAN HYDROGEL-CHELATOR FOR CANCER THERAPY | (주)카이바이오텍 | 2021-08-05 | — | — | WO | claimed |
| US-7282342-B2 | Methods for detecting weakly immunogenic analytes | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-10-16 | — | — | US | claimed |
| US-20070128660-A1 | Methods for detecting weakly immunogenic analytes | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-06-07 | — | — | US | claimed |
| US-20060035279-A1 | Anti-GPE antibodies, their uses and assays for weakly immunogenic molecules | NEUREN PHARMACEUTICALS LTD. (NZ) | 2006-02-16 | — | — | US | claimed |
| EP-0220858-B1 | MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES, CORRESPONDING HYBRIDOMAS, THE PRODUCTION AND USE THEREOF | CETUS CORP (US) | 1993-02-10 | — | — | EP | claimed |
| US-4938948-A | Diagnosis | CETUS CORPORATION (US) | 1990-07-03 | — | — | US | claimed |
| EP-0220858-A2 | Monoclonal anti-human breast cancer antibodies, corresponding hybridomas, the production and use thereof | CETUS ONCOLOGY CORPORATION (US) | 1987-05-06 | — | — | EP | claimed |
| US-20260146092-A1 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026102432-A1 | HUMAN ANTIBODIES TO MARBURG VIRUS AND METHODS OF USE THEREFOR | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4731640-A1 | IMMUNOREACTIVE PEPTIDES | Research Development Foundation (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720675-A2 | HUMAN MONOCLONAL ANTIBODIES FOR HUMAN PARAINFLUENZA VIRUS TYPE 3 | Vanderbilt University (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698566-A2 | AGNONISTIC ANTIBODIES TARGETING JAML | La Jolla Institute for Immunology (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12559545-B2 | Human hendra virus and nipah virus antibodies and methods of use therefor | VANDERBILT UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| US-4722899-A | INDUCE IMMUNOLOGICAL TOLERANCE TO SECOND ANTIGEN THEN IMMUNIZING WITH FIRST ANTIGEN | Hamaoka, Toshiyuki (JP) | 1988-02-02 | — | — | US | disclosed |
| EP-0203764-A2 | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0181061-A1 | Labelling organic molecules with sulphur-35 | AMERSHAM INTERNATIONAL plc (GB) | 1986-05-14 | — | — | EP | disclosed |
| EP-0063373-B1 | CELL-SPECIFIC GLYCOPEPTIDE LIGANDS | MERCK & CO. INC. (US) | 1986-03-12 | — | — | EP | disclosed |
| US-4386026-A | Cell-specific glycopeptide ligands | MERCK & CO., INC. (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0063373-A1 | Cell-specific glycopeptide ligands | MERCK & CO. INC. (US) | 1982-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146092-A1 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | PDCD1LG2, PDCD1, CD274 | ALDH1A1 2835/4885PKM 3343/4885POLB 2738/4885 |
| US-12559545-B2 | Human hendra virus and nipah virus antibodies and methods of use therefor | VSIG8, IGSF11, NIPSNAP1 | ALDH1A1 3333/4885PKM 4775/4885POLB 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.